Subscribe to RSS
DOI: 10.1055/s-0028-1109901
© Georg Thieme Verlag KG Stuttgart · New York
Diagnose und multimodale Therapie des hepatozellulären Karzinoms
Diagnosis and Multimodal Therapy for Hepatocellular CarcinomaPublication History
Manuskript eingetroffen: 30.7.2009
Manuskript akzeptiert: 29.10.2009
Publication Date:
29 January 2010 (online)

Zusammenfassung
Das hepatozelluläre Karzinom (HCC) ist weltweit eine der führenden krebsbedingten Todesursachen. Die Mehrzahl aller HCC entsteht auf dem Boden einer Leberzirrhose. Dies verkompliziert die Diagnostik und Therapie. Zur nicht invasiven Diagnostik sind klare Kriterien entwickelt worden, die auf kontrastverstärkten dynamischen bildgebenden Verfahren und dem Serum-Tumormarkerspiegel des AFP (Alpha-Fetoprotein) beruhen. Bei der Planung der Therapie müssen neben der Tumorausdehnung und -ausbreitung auch der Allgemeinzustand des Patienten und insbesondere die Leberfunktion mitberücksichtigt werden. Zur Einschätzung der Prognose und Planung der geeigneten Therapie hat sich hier insbesondere das BCLC-System der Barcelona Clinic for Liver Cancer bewährt. Nur etwa ein Drittel aller Patienten kann mittels Resektion, Transplantation oder lokaler Tumorablation kurativ behandelt werden. In den lokal fortgeschrittenen Fällen kommen v. a. transarterielle Verfahren wie die transarterielle Chemoembolisation und neuerdings die selektive interne Radiotherapie zum Einsatz. Da das HCC ein relativ chemotherapieresistenter Tumor ist, spielt die Chemotherapie kaum eine Rolle in der Therapie des HCC. Mit der Einführung des Sorafenib steht jetzt erstmals eine wirkungsvolle systemische Therapie für das fortgeschrittene und metastasierte HCC zur Verfügung. Einen besonderen Stellenwert hat die interdisziplinäre Betreuung von Patienten mit HCC, um alle für den einzelnen Patienten relevanten Therapieoptionen ausnutzen zu können.
Abstract
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death in the world. The majority of HCCs develops on the basis of a chronic liver disease. This often complicates diagnosis and therapy. Non-invasive diagnostic criteria are based on dynamic imaging techniques and the serum level of AFP (alpha-fetoprotein). When evaluating HCC patients for therapy, besides tumor burden and localisation, the therapeutic evaluation must also consider the general condition of the patient and his/her liver function. For this purpose, the BCLC algorithm of the Barcelona Clinic for Liver Disease has proven helpful. Only one-third of the patients can be cured by resection, transplantation or local tumour ablation. In locally advanced cases transarterial procedures including transarterial chemoembolisation and radioembolisation are applied. HCC is a chemo-resistant tumour and chemotherapy is not accepted as standard of care in HCC. Sorafenib is the first systemic treatment with proven efficacy approved for the treatment of advanced and metastatic HCC. Interdisciplinary management of HCC patients is essential in order to provide every patient with the optimal therapy at his specific stage of disease.
Schlüsselwörter
hepatozelluläres Karzinom - Lebertransplantation - transarterielle Chemoembolisation - Radiofrequenzablation - Sorafenib
Key words
hepatocellular carcinoma - liver transplantation - transarterial chemoembolisation - radiofrequency ablation - sorafenib
Literatur
- 1
Parkin D M, Bray F, Ferlay J. et al .
Estimating the world cancer burden: Globocan 2000.
Int J Cancer.
2001;
94
153-156
MissingFormLabel
- 2
Altekruse S, McGlynn K A, Reichman M E.
Hepatocellular carcinoma incidence, mortality, and survival trends in the United States
from 1975 to 2005.
J Clin Oncol.
2009;
27
1485-1491
MissingFormLabel
- 3 London W T, McGlynn K A. Liver cancer. Schottenfeld D, Fraumeni JF Jr Cancer Epidemiology and Prevention New York; Oxford University Press 2006 3. Aufl: 763-786
MissingFormLabel
- 4
Sun C A, Wu D M, Lin C C. et al .
Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective
study of 12,008 men in Taiwan.
Am J Epidemiol.
2003;
157
674-682
MissingFormLabel
- 5
Sakuma K, Saitoh N, Kasai M. et al .
Relative risks of death due to liver disease among Japanese male adults having various
statuses for hepatitis B s and e antigen/antibody in serum: a prospective study.
Hepatology.
1988;
8
1642-1646
MissingFormLabel
- 6
El-Serag H B, Tran T, Everhart J E.
Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.
Gastroenterology.
2004;
126
460-468
MissingFormLabel
- 7
Calle E E, Rodriguez C, Walker-Thurmond K. et al .
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of
U. S. adults.
N Engl J Med.
2003;
348
1625-1638
MissingFormLabel
- 8
Maylin S, Martinot-Peignoux M, Moucari R. et al .
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis
C.
Gastroenterology.
2008;
135
821-829
MissingFormLabel
- 9
George S L, Bacon B R, Brunt E M. et al .
Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy:
a 5-year follow-up of 150 patients.
Hepatology.
2009;
49
729-738
MissingFormLabel
- 10
D’Amico G, Garcia-Tsao G, Pagliaro L.
Natural history and prognostic indicators of survival in cirrhosis: a systematic review
of 118 studies.
J Hepatol.
2006;
44
217-231
MissingFormLabel
- 11
Bruix J, Sherman M.
AASLD Guideline: Management of hepatocellular carcinoma.
Hepatology.
2005;
42
1208-1236
MissingFormLabel
- 12
Matsui O.
Imaging of multistep human hepatocarcinogenesis by CT during intraarterial contrast
injection.
Intervirology.
2004;
47
271-276
MissingFormLabel
- 13
Kelekis N L, Semelka R C, Worawattanakul S. et al .
Hepatocellular carcinoma in North America: a multiinstitutional study of appearance
on T 1-weighted, T 2-weighted, and serial gadolinium-enhanced gradient-echo images.
Am J Roentgenol.
1998;
170
1005-1013
MissingFormLabel
- 14
Hwang G J, Kim M J, Yoo H S. et al .
Nodular hepatocellular carcinomas: detection with arterial-, portal-, and delayed-phase
images at spiral CT.
Radiology.
1997;
202
383-388
MissingFormLabel
- 15
Willatt J M, Hussain H K, Adusumilli S. et al .
MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies.
Radiology.
2008;
247
311-330
MissingFormLabel
- 16
Schacherer D, Girlich C, Jung M E. et al .
Transabdominal ultrasound with echoenhancement by contrast media in the diagnosis
of hepatocellular carcinoma.
Dig Dis.
2009;
27
109-113
MissingFormLabel
- 17
Kim S J, Kim S H, Lee J. et al .
Ferucarbotranenhanced 3.0-T magnetic resonance imaging using parallel imaging technique
compared with triple-phase multidetector row computed tomography for the preoperative
detection of hepatocellular carcinoma.
J Comput Assist Tomogr.
2008;
32
379-385
MissingFormLabel
- 18
Kim Y K, Kwak H S, Han Y M. et al .
Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic
resonance imaging and resovist-enhanced magnetic resonance imaging for the detection
of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography
and computed tomography arterioportography using 16-slice multidetector computed tomography.
J Comput Assist Tomogr.
2007;
31
702-711
MissingFormLabel
- 19
Kim S H, Kim S H, Lee J. et al .
Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection
of hepatocellular carcinoma.
Am J Roentgenol.
2009;
192
1675-1681
MissingFormLabel
- 20
Zech C J, Reiser M F, Herrmann K A.
Imaging of hepatocellular carcinoma by computed tomography and magnetic resonance
imaging: state of the art.
Dig Dis.
2009;
27
114-124
MissingFormLabel
- 21
Burrel M, Llovet J M, Ayuso C. et al .
Barcelona Clínic Liver Cancer Group. MRI angiography is superior to helical CT for
detection of HCC prior to liver transplantation: an explant correlation.
Hepatology.
2003;
38
1034-1042
MissingFormLabel
- 22
Stoker J, Romijn M G, Man R A. et al .
Prospective comparative study of spiral computer tomography and magnetic resonance
imaging for detection of hepatocellular carcinoma.
Gut.
2002;
51
105-107
MissingFormLabel
- 23
Marin de D, Di Martino M, Guerrisi A. et al .
Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate
dimeglumine-enhanced MR imaging and multiphasic 64-section CT.
Radiology.
2009;
251
85-95
MissingFormLabel
- 24
Kim K Y, Kim C S, Chung G H. et al .
Comparison of Gadobenate Dimeglumine-Enhanced dynamic MRI and 16-MDCT for the detection
of hepatocellular carcinoma.
Am J Roentgenol.
2006;
186
149-157
MissingFormLabel
- 25
Choi S H, Lee J M, Yu N C. et al .
Hepatocellular carinoma in liver transplantation candidates: detection with Gadobenate
Dimeglumine-enhanced MRI.
Am J Roentgenol.
2008;
191
529-536
MissingFormLabel
- 26
Kim S H, Choi B I, Lee J Y. et al .
Diagnostic Accuracy of Multi-/single-Detector row CT and contrast-enhanced MRI in
the detection of hepatocellular carcinomas meeting the Milan criteria before liver
transplantation.
Intervirology.
2008;
51
52-60
MissingFormLabel
- 27
Wang J H, Lu S N, Hung C H. et al .
Small hepatic nodules (≦ 2 cm) in cirrhosis patients: characterization with contrast-enhanced
ultrasonography.
Liver international.
2006;
26
928-934
MissingFormLabel
- 28
Dai Y, Chen M H, Fan Z H. et al .
Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients
with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced
helical computed tomography.
Hepatology Res.
2008;
38
281-290
MissingFormLabel
- 29
Park J W, Kim J H, Kim S K. et al .
A prospective evaluation of 18F-FDG and 11C-acetate PET/CT for detection of primary
and metastatic hepatocellular carcinoma.
J Nucl Med.
2008;
49
1912-1921
MissingFormLabel
- 30 Lamerz R, Hayes P, Hoffmann R T. et al .NACB: Practice guidelines and recommendations for use of tumour markers in the clinic-Liver
Cancer Manuscript (3D). 2005 http://www.nacb.org/lmpg/tumour_lmpg_draft.stm
MissingFormLabel
- 31
Chen D, Sung J, Shen J. et al .
Serum alpha-fetoprotein in early stages of human hepatocellular carcinoma.
Gastroenterology.
1984;
86
1404-1409
MissingFormLabel
- 32
Soreide O, Czerniak A, Bradpiece H. et al .
Characteristics of fibrolamellar hepatocellular carcinoma. A study of nine cases and
review of the literature.
Am J Surg.
1986;
151
518-523
MissingFormLabel
- 33
Fasani P, Sangiovanni A, De Fazio C. et al .
High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis
attributable to multiple risk factors.
Hepatology.
1999;
29
1704-1707
MissingFormLabel
- 34
Mita Y, Aoyagi Y, Yanagi M. et al .
The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay
in the early diagnosis of patients with hepatocellular carcinoma.
Cancer.
1998;
82
1643-1648
MissingFormLabel
- 35
Okuda H, Nakanishi T, Takatsu K. et al .
Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular
carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Cancer.
1999;
85
812-818
MissingFormLabel
- 36
Tanaka Y, Kashiwagi T, Tsutsumi H. et al .
Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular
carcinoma.
Hepatogastroenterology.
1999;
46
2464-2468
MissingFormLabel
- 37
Okuda H, Nakanishi T, Takatsu K. et al .
Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay
kit with increased sensitivity in relation to clinicopathologic features of solitary
hepatocellular carcinoma.
Cancer.
2000;
88
544-549
MissingFormLabel
- 38
Marrero J A, Su G L, Wei W. et al .
Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant
chronic liver disease in american patients.
Hepatology.
2003;
37
1114-1121
MissingFormLabel
- 39
Capurro M, Wanless I R, Sherman M. et al .
Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.
Gastroenterology.
2003;
125
89-97
MissingFormLabel
- 40
Sung Y K, Hwang S Y, Park M K. et al .
Glypican-3 is overexpressed in human hepatocellular carcinoma.
Cancer Sci.
2003;
94
259-262
MissingFormLabel
- 41
Hippo Y, Watanabe K, Watanabe A. et al .
Identification of soluble NH 2-terminal fragment of glypican-3 as a serological marker
for early-stage hepatocellular carcinoma.
Cancer Res.
2004;
64
2418-2423
MissingFormLabel
- 42
Marrero J A, Romano P R, Nikolaeva O. et al .
GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocullular carcinoma.
J Hepatol.
2005;
43
1007-1012
MissingFormLabel
- 43
Ishizawa T, Hasegawa K, Aoki T. et al .
Neither multiple tumors nor portal hypertension are surgical contraindications for
hepatocellular carcinoma.
Gastroenterology.
2008;
134
1908-1916
MissingFormLabel
- 44
Shirabe K, Shimada M, Gion T. et al .
Postoperative liver failure after major hepatic resection for hepatocellular carcinoma
in the modern era with special reference to remnant liver volume.
J Am Coll Surg.
1999;
188
304-309
MissingFormLabel
- 45
Okamoto E, Kyo A, Yamanaka N. et al .
Prediction of the safe limits of hepatectomy by combined volumetric and functional
measurements in patients with impaired hepatic function.
Surgery,.
1984;
95
586-592
MissingFormLabel
- 46
Abdalla E K, Hicks M E, Vauthey J N.
Portal vein embolization: rationale, technique and future prospects.
Br J Surg.
2001;
88
165-175
MissingFormLabel
- 47
Farges O, Belghiti J, Kianmanesh R. et al .
Portal vein embolization before right hepatectomy: prospective clinical trial.
Ann Surg.
2003;
237
208-217
MissingFormLabel
- 48
Sasaki A, Iwashita Y, Shibata K. et al .
Preoperative transcatheter arterial chemoembolization reduces long-term survival rate
after hepatic resection for resectable hepatocellular carcinoma.
Eur J Surg Oncol.
2006;
32
773-779
MissingFormLabel
- 49
Helmberger T, Dogan S, Straub G. et al .
Liver resection or combined chemoembolization and radiofrequency ablation improve
survival in patients with hepatocellular carcinoma.
Digestion.
2007;
75
104-112
MissingFormLabel
- 50
Regimbeau J M, Kianmanesh R, Farges O. et al .
Extent of liver resection influences the outcome in patients with cirrhosis and small
hepatocellular carcinoma.
Surgery.
2002;
131
311-317
MissingFormLabel
- 51
Fan S T, Lo C M, Liu C L. et al .
Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths.
Ann Surg.
1999;
229
322-330
MissingFormLabel
- 52
Poon R T, Ng I O, Fan S T. et al .
Clinicopathologic features of long-term survivors and disease-free survivors after
resection of hepatocellular carcinoma: a study of a prospective cohort.
J Clin Oncol.
2001;
19
3037-3044
MissingFormLabel
- 53
Morris-Stiff G, Gomez D, Liguori Carino de N. et al .
Surgical management of hepatocellular carcinoma: Is the jury still out?.
Surg Oncol.
2009;
18
298-321
MissingFormLabel
- 54
Portolani N, Coniglio A, Ghidoni S. et al .
Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic
and therapeutic implications.
Ann Surg.
2006;
243
229-235
MissingFormLabel
- 55
Mazzaferro V, Regalia E, Doci R. et al .
Liver transplantation for the treatment of small hepatocellular carcinomas in patients
with cirrhosis.
N Engl J Med.
1996;
334
693-699
MissingFormLabel
- 56
Iwatsuki S, Starzl T E, Sheahan D G. et al .
Hepatic resection versus transplantation for hepatocellular carcinoma.
Ann Surg.
1991;
214
221-228
MissingFormLabel
- 57
Colella G, Bottelli R, De Carlis L. et al .
Hepatocellular carcinoma: comparison between liver transplantation, resective surgery,
ethanol injection, and chemoembolization.
Transpl Int.
1998;
11
193-196
MissingFormLabel
- 58
Yoo H Y, Patt C H, Geschwind J F. et al .
The outcome of liver transplantation in patients with hepatocellular carcinoma in
the United States between 1988 and 2001: 5-year survival has improved significantly
with time.
J Clin Oncol.
2003;
21
4329-4335
MissingFormLabel
- 59
Yao F Y, Ferrell L, Bass N M. et al .
Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF
criteria with the Milan criteria and the Pittsburgh modified TNM criteria.
Liver Transpl.
2002;
8
765-774
MissingFormLabel
- 60
Mazzaferro V, Llovet J M, Miceli R. et al .
Metroticket Investigator Study Group. Predicting survival after liver transplantation
in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective,
exploratory analysis.
Lancet Oncol.
2009;
10
35-43
MissingFormLabel
- 61
Decaens T, Roudot-Thoraval F, Bresson-Hadni S. et al .
Impact of pretransplantation transarterial chemoembolization on survival and recurrence
after liver transplantation for hepatocellular carcinoma.
Liver Transpl.
2005;
11
767-775
MissingFormLabel
- 62
Chapman W C, Majella Doyle M B, Stuart J E. et al .
Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular
carcinoma before liver transplantation.
Ann Surg.
2008;
248
617-625
MissingFormLabel
- 63
Ebara M, Okabe S, Kita K. et al .
Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy
based on 20-year observation.
J Hepatol.
2005;
43
458-464
MissingFormLabel
- 64
Lencioni R, Crocetti L.
Image-guided thermal ablation of hepatocellular carcinoma.
Critical Reviews in Oncology/Hematology.
2008;
66
200-207
MissingFormLabel
- 65
Lencioni R, Bartolozzi C, Caramella D. et al .
Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis
of prognostic factors in 105 Western patients.
Cancer.
1995;
76
1737-1746
MissingFormLabel
- 66
Livraghi T, Giorgio A, Marin G. et al .
Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous
ethanol injection.
Radiology.
1995;
197
101-108
MissingFormLabel
- 67
Chen M S, Li J Q, Zheng Y. et al .
A prospective randomized trial comparing percutaneous local ablative therapy and partial
hepatectomy for small hepatocellular carcinoma.
Annals of Surgery.
2006;
243
321-328
MissingFormLabel
- 68
Koda M, Murawaki Y, Mitsuda A. et al .
Predictive factors for intrahepatic recurrence after percutaneous ethanol injection
therapy for small hepatocellular carcinoma.
Cancer.
2000;
88
529-537
MissingFormLabel
- 69
Lencioni R A, Allgaier H P, Cioni D. et al .
Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency
thermal ablation versus percutaneous ethanol injection.
Radiology.
2003;
228
235-240
MissingFormLabel
- 70
Lin S M, Lin C J, Lin C C. et al .
Randomised controlled trial comparing percutaneous radiofrequency thermal ablation,
percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular
carcinoma of 3 cm or less.
Gut.
2005;
54
1151-1156
MissingFormLabel
- 71
Shiina S, Teratani T, Obi S. et al .
A randomized controlled trial of radiofrequency ablation with ethanol injection for
small hepatocellular carcinoma.
Gastroenterology.
2005;
129
122-130
MissingFormLabel
- 72
Choi D, Lim H K, Rhim H. et al .
Percutaneous radiofrequency ablation for early-stage hepatocellular carcinoma as a
first-line treatment: long-term results and prognostic factors in a large single-institution
series.
European Radiology.
2007;
17
684-692
MissingFormLabel
- 73
Lencioni R, Cioni D, Crocetti L. et al .
Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results
of percutaneous image-guided radiofrequency ablation.
Radiology.
2005;
234
961-967
MissingFormLabel
- 74
Tateishi R, Shiina S, Teratani T. et al .
Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of
1000 cases.
Cancer.
2005;
103
1201-1209
MissingFormLabel
- 75
Livraghi T, Meloni F, Di Stasi M. et al .
Sustained complete response and complications rates after radiofrequency ablation
of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment
of choice?.
Hepatology.
2008;
47
82-89
MissingFormLabel
- 76
Yin X Y, Xie X Y, Lu M D. et al .
Percutaneous thermal ablation of medium and large hepatocellular carcinoma: long-term
outcome and prognostic factors.
Cancer.
2009;
115
1914-1923
MissingFormLabel
- 77
Marelli L, Stigliano R, Triantos C. et al .
Transarterial therapy for hepatocellular carcinoma: which technique is more effective?
A systematic review of cohort and randomized studies.
Cardiovasc Intervent Radiol.
2007;
30
6-25
MissingFormLabel
- 78
Wang J H, Changchien C S, Hu T H. et al .
The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging
for hepatocellular carcinoma – Survival analysis of 3892 patients.
Eur J Cancer.
2008;
44
1000-1006
MissingFormLabel
- 79
Varela M, Real M I, Burrel M. et al .
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and
doxorubicin pharmacokinetics.
J Hepatol.
2007;
46
474-481
MissingFormLabel
- 80
Camma C, Schepis F, Orlando A. et al .
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis
of randomized controlled trials.
Radiology.
2002;
224
47-54
MissingFormLabel
- 81
Llovet J M, Burroughs A, Bruix J.
Hepatocellular carcinoma.
Lancet.
2003;
362
1907-1917
MissingFormLabel
- 82
Llovet J M, Real M I, Montana X. et al .
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients
with unresectable hepatocellular carcinoma: a randomised controlled trial.
Lancet.
2002;
359
1734-1739
MissingFormLabel
- 83
Bruix J, Llovet J M, Castells A. et al .
Transarterial embolization versus symptomatic treatment in patients with advanced
hepatocellular carcinoma: results of a randomized, controlled trial in a single institution.
Hepatology.
1998;
27
1578-1583
MissingFormLabel
- 84
Chang J M, Tzeng W S, Pan H B. et al .
Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular
carcinoma. A randomized controlled study.
Cancer.
1994;
74
2449-2453
MissingFormLabel
- 85
Kawai S, Okamura J, Ogawa M. et al .
Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma--a
comparison of lipiodol-transcatheter arterial embolization with and without adriamycin
(first cooperative study). The Cooperative Study Group for Liver Cancer Treatment
of Japan.
Cancer Chemother Pharmacol.
1992;
31 (Suppl)
1-6
MissingFormLabel
- 86
Lencioni R, Malagari K, Vogl T. et al .
A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular
carcinoma by transcatheter arterial chemoembolization.
J Clin Oncol.
2009;
27
4523
MissingFormLabel
- 87
Kulik L M, Carr B I, Mulcahy M F. et al .
Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without
portal vein thrombosis.
Hepatology.
2008;
47
71-81
MissingFormLabel
- 88
Ho S, Lau W Y, Leung T W. et al .
Clinical evaluation of the partition model for estimating radiation doses from yttrium-90
microspheres in the treatment of hepatic cancer.
Eur J Nucl Med.
1997;
24
293-298
MissingFormLabel
- 89
Lau W Y, Ho S, Leung T W. et al .
Selective internal radiation therapy for nonresectable hepatocellular carcinoma with
intraarterial infusion of 90yttrium microspheres.
Int J Radiat Oncol Biol Phys.
1998;
40
583-592
MissingFormLabel
- 90
Lau W Y, Ho S, Leung W T. et al .
What determines survival duration in hepatocellular carcinoma treated with intraarterial
Yttrium-90 microspheres?.
Hepatogastroenterology.
2001;
48
338-340
MissingFormLabel
- 91
Sangro B, Bilbao J I, Boan J. et al .
Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular
carcinoma.
Int J Radiat Oncol Biol Phys.
2006;
66
792-800
MissingFormLabel
- 92
Geschwind J F, Salem R, Carr B I. et al .
Yttrium-90 microspheres for the treatment of hepatocellular carcinoma.
Gastroenterology.
2004;
127
194-205
MissingFormLabel
- 93
Salem R, Lewandowski R J, Atassi B. et al .
Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere):
safety, tumor response, and survival.
J Vasc Interv Radiol.
2005;
16
1627-1639
MissingFormLabel
- 94
Kulik L M, Atassi B, Holsbeeck van L. et al .
Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma:
downstaging to resection, RFA and bridge to transplantation.
J Surg Oncol.
2006;
94
572-586
MissingFormLabel
- 95
Lawrence T S, Robertson J M, Anscher M S. et al .
Hepatic toxicity resulting from cancer treatment.
Int J Rad Oncol Biol Phys.
1995;
31
1237-1248
MissingFormLabel
- 96
Lawrence T S, Ten Haken R, Kessler M.
The use of 3-D dose volume analysis to predict radiation hepatitis.
Int J Rad Oncol Biol Phys.
1992;
23
781-788
MissingFormLabel
- 97
Phillips R, Murikami K.
Primary neoplasma of the liver. Results of radiation therapy.
Cancer.
1960;
13
714-720
MissingFormLabel
- 98
Notsumata K, Okazaki A, Yokohama T.
Radiotherapy for advanced hepatocellular carcinoma.
Acta Hepatol Jpn.
1992;
33
611-616
MissingFormLabel
- 99
Takagi H, Takayama H, Yamada S.
Radiation therapy to the hepatocellular carcinoma.
Jpn J Gastroenterol.
1989;
86
237-245
MissingFormLabel
- 100
Tang Z Y.
Treatment of primary liver cancer – with special reference to the east part of china.
Ann Acad Med.
1980;
9
251-262
MissingFormLabel
- 101
Li B, Yu J, Wang L. et al .
Study of local three-dimensional conformal radiotherapy combined with transcatheter
arterial chemoembolization for patients with Stage III hepatocellular carcinoma.
Am J Clin Oncol.
2003;
26
e92-e99
MissingFormLabel
- 102
Cheng J C, Wu J K, Huang C M. et al .
Dosimetric analysis and comparison of three-dimensional conformal radiotherapy and
intensity-modulated radiation therapy for patients with hepatocellular carcinoma and
radiation-induced liver disease.
Int J Radiat Oncol Biol Phys.
2003;
56
229-234
MissingFormLabel
- 103
Guo W J, Yu E X, Liu L M. et al .
Comparison between chemoembolization combined with radiotherapy and chemoembolization
alone for large hepatocellular carcinoma.
World J Gastroenterol.
2003;
9
1697-1701
MissingFormLabel
- 104
Yamada K, Izaki K, Sugimoto K. et al .
Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional
conformal radiotherapy for portal vein tumor thrombus in patients with unresectable
hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys.
2003;
57
113-119
MissingFormLabel
- 105
Wu D H, Liu L, Chen L H.
Therapeutic effects and prognostic factors in three-dimensional conformal radiotherapy
combined with transcatheter arterial chemoembolization for hepatocellular carcinoma.
World J Gastroenterol.
2004;
10
2184-2189
MissingFormLabel
- 106
Park W, Lim D H, Paik S W. et al .
Local radiotherapy for patients with unresectable hepatocellular carcinoma.
Int J Radiat Oncol Biol Phys.
2005;
61
1143-1150
MissingFormLabel
- 107
Louafi S, Boige V, Ducreux M. et al .
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma
(HCC): results of a phase II study.
Cancer.
2007;
109
1384-1390
MissingFormLabel
- 108
Becker G, Allgaier H P, Olschewski M. et al .
HECTOR Study Group. Long-acting octreotide versus placebo for treatment of advanced
HCC: a randomized controlled double-blind study.
Hepatology.
2007;
45
9-15
MissingFormLabel
- 109
Kawata S, Yamasaki E, Nagase T. et al .
Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma.
A randomized controlled trial.
Br J Cancer.
2001;
84
886-891
MissingFormLabel
- 110
Abou-Alfa G K, Schwartz L, Ricci S. et al .
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
J Clin Oncol.
2006;
24
4293-4300
MissingFormLabel
- 111
Llovet J M, Ricci S, Mazzaferro V. et al .
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med.
2008;
359
378-390
MissingFormLabel
- 112
Cheng A L, Kang Y K, Chen Z. et al .
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled
trial.
Lancet Oncol.
2009;
10
25-34
MissingFormLabel
- 113
So B J, Bekaii-Saab T, Bloomston M A. et al .
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in
a patient with hemochromatosis: A case report.
Journal of Hematology and Oncology.
2008;
1
18
MissingFormLabel
- 114
Llovet J, Mena C, Shan M. et al .
Biomarkers predicting outcome of patients with hepatocellular carcinoma: results from
the randomized phase III sharp trial.
Hepatology.
2008;
48 (Suppl)
372A (abstract 149)
MissingFormLabel
- 115
Perforierte Ulzerationen der Speiseröhre und Mediastinitis mit Todesfolge nach Sorafenib
(Nexavar).
Deutsches Ärzteblatt.
2009;
106
A476
MissingFormLabel
- 116
Miller A A, Murry D J, Owzar K. et al .
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction:
CALGB 60 301.
J Clin Oncol.
2009;
27
1800-1805
MissingFormLabel
- 117
Zhu A X, Sahani D V, Duda D G. et al .
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular
Carcinoma: A Phase II Study.
J Clin Oncol.
2009;
27
3027-3035
MissingFormLabel
- 118
Siegel A B, Cohen E I, Ocean A. et al .
Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable
hepatocellular carcinoma.
J Clin Oncol.
2008;
26
2992-2998
MissingFormLabel
- 119
Thomas M B, Chadha R, Glover K. et al .
Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma.
Cancer.
2007;
110
1059-1067
MissingFormLabel
- 120
Philip P A, Mahoney M R, Allmer C. et al .
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.
J Clin Oncol.
2005;
23
6657-6663
MissingFormLabel
- 121
Zhu A X, Blaszkowsky L S, Ryan D P. et al .
Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients
with advanced hepatocellular carcinoma.
J Clin Oncol.
2006;
24
1898-1903
MissingFormLabel
- 122
Thomas M B, Morris J S, Chadha R. et al .
Phase II Trial of the combination of bevacizumab and erlotinib in patients who have
advanced hepatocellular carcinoma.
J Clin Oncol.
2009;
27
843-850
MissingFormLabel
- 123
Zhu A X, Stuart K, Blaszkowsky L S. et al .
Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
Cancer.
2007;
110
581-589
MissingFormLabel
- 124
Park B H, Hwang T, Liu T C. et al .
Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary
or metastatic liver cancer: a phase I trial.
Lancet Oncol.
2008;
9
533-542
MissingFormLabel
- 125
Liu T C, Hwang T, Park B H. et al .
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and
anti-HBV activities in patients with hepatocellular carcinoma.
Mol Ther.
2008;
16
1637-1642
MissingFormLabel
- 126
Yamasaki S, Hasegawa H, Kinoshita H. et al .
A prospective randomized trial of the preventive effect of pre-operative transcatheter
arterial embolization against recurrence of hepatocellular carcinoma.
Jpn J Cancer Res.
1996;
87
206-211
MissingFormLabel
- 127
Wu C C, Ho Y Z, Ho W L. et al .
Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular
carcinoma: a reappraisal.
Br J Surg.
1995;
82
122-126
MissingFormLabel
- 128
Sala M, Llovet J M, Vilana R. et al .
Barcelona Clínic Liver Cancer Group. Initial response to percutaneous ablation predicts
survival in patients with hepatocellular carcinoma.
Hepatology.
2004;
40
1352-1360
MissingFormLabel
- 129
Cammà C, Di Marco V, Orlando A. et al .
Treatment of hepatocellular carcinoma in compensated cirrhosis with radio-frequency
thermal ablation (RFTA): a prospective study.
J Hepatol.
2005;
42
535-540
MissingFormLabel
- 130
Zhang Y J, Liang H H, Chen M S. et al .
Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol
injection: a prospective randomized trial.
Radiology.
2007;
244
599-607
MissingFormLabel
- 131
Lencioni R, Pinto F, Armillotta N. et al .
Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma
in cirrhosis: a European experience.
Eur Radiol.
1997;
7
514-519
MissingFormLabel
- 132
Arii S, Yamaoka Y, Futagawa S. et al .
Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas:
a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan.
Hepatology.
2000;
32
1224-1229
MissingFormLabel
- 133
Taniguchi M, Kim S R, Imoto S. et al .
Long-term outcome of percutaneous ethanol injection therapy for minimum-sized hepatocellular
carcinoma.
World J Gastroenterol.
2008;
14
1997-2002
MissingFormLabel
- 134
Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire .
A comparison of lipiodol chemoembolization and conservative treatment for unresectable
hepatocellular carcinoma.
N Engl J Med.
1995;
332
1256-1261
MissingFormLabel
- 135
Lo C M, Ngan H, Tso W K. et al .
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable
hepatocellular carcinoma.
Hepatology.
2002;
35
1164-1171
MissingFormLabel
- 136
Sciarrino E, Simonetti R G, Le Moli S. et al .
Adriamycin treatment for hepatocellular carcinoma. Experience with 109 patients.
Cancer.
1985;
56
2751-2755
MissingFormLabel
- 137
Lai C L, Wu P C, Chan G C. et al .
Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A
prospective randomized trial.
Cancer.
1988;
62
479-483
MissingFormLabel
- 138
Lee J, Park J O, Kim W S. et al .
Phase II study of doxorubicin and cisplatin in patients with metastatic hepatocellular
carcinoma.
Cancer Chemother Pharmacol.
2004;
54
385-390
MissingFormLabel
- 139
Yeo W, Mok T S, Zee B. et al .
A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil
(PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.
J Natl Cancer Inst.
2005;
19
1532-1538
MissingFormLabel
- 140
Yang T S, Lin Y C, Chen J S. et al .
Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma.
Cancer.
2000;
89
750-756
MissingFormLabel
- 141
Patt Y Z, Hassan M M, Aguayo A. et al .
Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma,
and gallbladder carcinoma.
Cancer.
2004;
101
578-586
MissingFormLabel
- 142
Boige V, Raoul J L, Pignon J P. et al .
Fédération Francophone de Cancérologie Digestive. Multicentre phase II trial of capecitabine
plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD
03 – 03 trial.
Br J Cancer.
2007;
97
862-867
MissingFormLabel
- 143
Bruix J, Llovet J M.
Major achievements in hepatocellular carcinoma.
Lancet.
2009;
373
614-616
MissingFormLabel
- 144
Llovet J M, Bruix J.
Molecular targeted therapies in hepatocellular carcinoma.
Hepatology.
2008;
48
1312-1327
MissingFormLabel
Prof. Dr. Frank T. Kolligs
Medizinische Klinik und Poliklinik II, Klinikum der Universität München, Campus Großhadern
Marchioninistraße 15
81377 München
Email: fkolligs@med.uni-muenchen.de